AMRI and Ono extend drug discovery pact

Will collaborate on hit-to-lead and lead optimisation for two new molecules

AMRI has entered into a new five-year service agreement with Ono Pharmaceutical Company, headquartered in Osaka, Japan. AMRI will provide a range of services from early drug discovery to cGMP manufacturing.

The two companies have already agreed to medicinal chemistry projects within the new framework and will collaborate on additional hit-to-lead and lead optimisation for two new molecules. The work will take place at AMRIís laboratories in Albany, NY, US.

An early adopter of the AMRI Smartsourcing concept, Ono has been using AMRIís integrated global facilities and capabilities for projects ranging from early drug discovery, including high-throughput screening (HTS), biology support and computer-aided drug discovery (CADD), to multiple medicinal chemistry and a variety of drug development and cGMP programmes.